Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe immune cells to predict transplant rejection

NCT ID NCT03016455

Knowledge-focused Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 116 kidney transplant patients to understand how B cells (a type of immune cell) behave in those who develop donor-specific antibodies or chronic rejection. Researchers analyzed blood samples to find patterns that could serve as early warning signs. The goal is to improve future treatments by identifying who is at risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to predict and treat antibody-mediated rejection in kidney transplant patients.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

116 people

The number who actually took part.

Started

Jun 2013

Finished

Dec 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

100 kidney graft recipients with DSA or cAMR (renal dysfunction, positive DSA, allograft nephropathy), and 25 stable patients of 13 French transplantation centres.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria : * Non stable patients : * Patient older than 18 years old. * Patient which is the recipient of a renal transplant * Patient who develops anti donor antibodies after the transplantation and / or suffering from a histologically-proven antibody mediated rejection. * Patient who has signed an informed consent form * Stable patients : * Patient older than 18 years old. * Patient that is the recipient of a renal transplant for more than one year * Patient who has accepted to participate in the Brest Kidney graft recipient collection * Patient that is not suffering from any rejection, that has a good renal function and a low proteinuria * Patient that has not developed any DSA. Exclusion criteria : \- Patients that has not signed the consent form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic antibody mediated rejection (CAMR) in kidney transplant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal transplant

Contacts and locations

Locations

  • APHP Hôpital Necker

    Paris, 75743, France

  • CHU Amiens

    Amiens, 80054, France

  • CHU Brest

    Brest, 29200, France

  • CHU CAEN

    Caen, 14033, France

  • CHU Limoges

    Limoges, 87042, France

  • CHU Poitiers

    Poitiers, 86021, France

  • CHU Reims

    Reims, 51092, France

  • CHU Rennes

    Rennes, 35033, France

  • CHU Rouen

    Rouen, 76230, France

  • CHU Tours

    Tours, 37044, France

  • Chu Angers

    Angers, 49933, France

  • Chu Clermont Ferrand

    Clermont-Ferrand, 63003, France

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.